New gene therapy trial shows promise for heart disease treatment
新基因療法試驗在心臟病治療方面展現前景
更新於: 2026年6月3日 上午05:00
A groundbreaking era in cardiovascular medicine is dawning, with recent advances in gene therapy offering new hope for heart disease patients.
心血管醫學正迎來一個具開創性的時代，近期基因治療的進展為心臟病患者提供了新的希望。
Rather than relying on lifelong daily medications, scientists are developing "one-and-done" treatments that target the genetic root of cardiovascular issues.
科學家們正在研發「一次性」治療方法，旨在針對心血管疾病的基因根源，而非依賴終身服藥。
One major development is VERVE-102, a CRISPR-based therapy designed to disable the PCSK9 gene in the liver.
一項重大的進展是 VERVE-102，這是一種基於 CRISPR 的療法，旨在停用肝臟中的 PCSK9 基因。
By doing so, it helps the body clear LDL cholesterol more effectively.
藉此，它能幫助身體更有效地清除低密度脂蛋白膽固醇。
In recent clinical trials, the highest dose of this single-infusion treatment reduced LDL cholesterol by up to 62%, showing potential durability for over a year.
在最近的臨床試驗中，這種單次輸注治療的最高劑量可將低密度脂蛋白膽固醇降低達 62%，並展現出超過一年的潛在持久性。
As this technology evolves, the medical community remains focused on integrating these powerful tools ethically, marking a potential shift from managing chronic heart disease to finding lasting cures.
隨著這項技術的演進，醫學界仍專注於倫理地整合這些強大的工具，標誌著從管理慢性心臟病向尋求根治方法的潛在轉變。
